Skip to main content

Cardiovascular Disease Risk

Because of its safety and analgesic efficacy, the American Heart Association has identified acetaminophen as a first-line pain relief option for patients with, or at high risk for, cardiovascular disease.3*

50 million American adults are on aspirin heart therapy4

NSAIDs like ibuprofen bind to the cyclooxygenase-1 (COX-1) enzyme, which can interfere with aspirin’s ability to bind to COX-1 and exert its antiplatelet effect. TYLENOL® does not interfere with aspirin.1

Watch Ibuprofen interfere with aspirin’s cardiovascular benefits1

Ibuprofen binds to cyclooxygenase 1 (COX-1), which can interfere with aspirin heart therapy1

Aspirin binds to platelet COX-1 to inhibit platelet aggregation and to protect against myocardial infarction. Ibuprofen binds to the same area of the COX-1 enzyme. When a patient takes ibuprofen prior to taking aspirin, aspirin is blocked from reaching its binding sites.1

Plus, adding an NSAID to aspirin can increase the risk of stomach bleeding.5

NSAIDs may affect blood pressure2

OTC NSAID labels warn that patients with high blood pressure should ask a clinician before use. NSAIDs may interfere with some antihypertensive medicines, compromising blood pressure control.6

TYLENOL® may be appropriate for patients on certain antihypertensives.2,7

Cardiovascular Disease Icon

92.1 million American adults have at least 1 type of cardiovascular disease8†  

When recommending an analgesic, it’s important to take patients’ cardiovascular disease treatment into account. The combination of certain pain relievers with some medicinal therapies can cause additional medical issues.1,2

TYLENOL® and Cardiovascular Disease

An appropriate analgesic choice for your CV disease patients1,2

TYLENOL® does not have a cardiovascular warning on its OTC label and may be an appropriate analgesic option for patients with cardiovascular disease.9

Pill bottle icon

All OTC non-aspirin NSAID product labels have the following cardiovascular risk warning:

“NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed.”9

Order patient resources

Get complimentary samples and coupons, condition-focused patient education, and more.

*When symptoms are not controlled by nonpharmacological approaches.
†Study defines cardiovascular disease as hypertension, myocardial infarction, angina pectoris, heart failure, and stroke.

REFERENCES: 1. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 2. Elliott WJ. Drug interactions and drugs that affect blood pressure. J Clin Hypertens. 2006;8(10):731-737. 3. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642. 4. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. JAMA. 2007;297(18):2018-2024. 5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;118(8):1894-1909. 6. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. Ann Intern Med. 1987;107:628-635. 7. Horn JR, Hansten PD. NSAIDs and antihyperintensive agents. Pharmacy Times. Published April 1, 2006. Accessed January 5, 2017.8. Benjamin EJ, Blaha MJ, Chiuve S, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135;e1-e458. 9. Data on file. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Fort Washington, PA; 2017. 10. Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and